PhD Scientific Days 2023

Mental Health Sciences - Posters N

RTMS in schizophrenia to ameliorate negative symptoms

Előadó neve

Dr. Orban-Szigeti, Boglarka

Neptun code

dyfykv

Előadó munkahelye

Semmelweis University Department Psychiatry and Psychotherapy

Előadó telefonszáma

0036208259168

Előadó e-mail címe

orbanbogi@yahoo.com

Az előadás címe

RTMS in schizophrenia to ameliorate negative symptoms

Szerző(k) neve és munkahelye

dr. ORBÁN-SZIGETI BOGLÁRKA, Semmelweis University Department of Psychiatry and Psychotherapy, Budapest
Dr. Csukly Gábor, Semmelweis University Department of Psychiatry and Psychotherapy, Budapest

Bemutatás módja

Poszter

Szekció

Mental Health Sciences - Posters N

Language of the presentation

Hungarian

Preferred session

Mental Sciences

Összefoglaló szövege

Background
When it comes to negative and cognitive symptoms of schizophrenia the effectiveness of conventional treatments and antipsychotics are limited. While there is emerging clinical evidence that new augmented rTMS protocols are effective in depression, data on augmented therapies in schizophrenia is insufficient. Some, but not all patients respond to the given stimulations, which may present a correlation with the location of the stimuli, difference of the patterns of network impairments in subjects.
Methods
We planned an augmented theta-burst stimulation protocol by stimulating both locations connected to negative symptoms: the left Dorsolateral Prefrontal Cortex (DLPFC), and the vermis of the cerebellum. Fifty subjects with schizophrenia or schizoaffective disorder presenting negative symptoms, age between 18-55 years will be randomized to active and sham stimulation. The TBS protocol we adopted follows the standard TBS parameters, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. We plan to deliver 1800 stimuli to the left DLPFC and 1800 stimuli to the vermis on weekdays for four weeks, as an additional therapy to the regular antipsychotic taken by the patient. The primary endpoint is the change in negative symptom severity measured by the Positive and Negative Syndrome Scale (PANSS). Secondary efficacy endpoint is the safety outcome, the number of serious adverse events. Recently two meta-analyses have been published on the topic, showing that the effectiveness of the left DLPC intermittent TMS treatment is comparable to the effect of clozapine.
Discussion
This is a double-blind, sham-controlled, randomized study to assess the efficacy and safety of an augmented theta-burst rTMS treatment in schizophrenia. We hypothesize that negative symptoms of patients on active therapy will improve significantly compared to patients on sham treatment.

University and Doctoral School

Semmelweis University, János Szentágothai Doctoral School of Neurosciences

Supervisor

Dr. Csukly Gábor

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7513

Start

11:18

End

11:23

Authors (legacy)

dr. ORBÁN-SZIGETI BOGLÁRKA, Semmelweis University Department of Psychiatry and Psychotherapy, Budapest
Dr. Csukly Gábor, Semmelweis University Department of Psychiatry and Psychotherapy, Budapest